News 2024-03-02
Porton Pharma Solutions Joined the SBTi to Drive Climate Action
Porton Pharma Solutions Ltd. is thrilled to announce its commitment to climate action by joining the Science Based Targets initiative (SBTi). By aligning our emissions reduction targets with the Paris Agreement goals on limiting global warming to 1.5°C, we aim to contribute towards creating a sustainable and low-carbon future.
By joining the SBTi, Porton commits to setting ambitious, science-based greenhouse gas (GHG) emissions reduction near term targets in line with the goals outlined in the Paris Agreement. These targets will be developed using the most up-to-date climate science available and will ensure that our emissions trajectory is consistent with the global effort to limit temperature rise below dangerous levels.
"We are excited to join the SBTi and commit to science-based targets, which remarks another milestone in Porton’s actions to mitigate climate change, " said Oliver Ju, Chairman of Porton. "By doing so, we are taking concrete actions to address climate change and contribute to the global collective effort. In 2023, we established a task force to comprehensively advance and implement our initiatives concerning climate change. We believe that businesses have a crucial role in leading the transition to a sustainable future, and we are committed to doing our part."
As part of our commitment to the SBTi, Porton will regularly measure and report our progress towards our targets, providing transparency and accountability to our stakeholders. Through this process, we will identify opportunities for innovation and efficiency, promoting sustainable practices throughout our operations and supply chain.
About SBTi
The Science Based Targets initiative (SBTi) is a partnership between CDP, the United Nations Global Compact, World Resources Institute (WRI) and the World Wide Fund for Nature (WWF), aiming to drive ambitious climate action in the private sector by enabling organizations to set science-based emissions reduction targets.
Others
More
News 2025-03-21
Porton's Near-Term Target Validated by the SBTi
March 20, 2025, Chongqing—Porton Pharma Solutions Ltd. (Porton) announced today that its near-term greenhouse gas emissions reductions targets have been formally validated by the Science Based Targets initiative (SBTi). This milestone not only signifies its strategic breakthrough in climate governance, but also demonstrates that its decarbonization roadmap is aligned with the 1.5°C climate mitigation pathway.
News 2025-03-19
Porton Advanced Announces Collaboration with Eureka Therapeutics to Accelerate T Cell Therapy Development
Cranbury, New Jersey, March 19, 2025 — Porton Advanced, a leading contract development and manufacturing organization (CDMO) specializing in advanced therapy medicinal products (ATMPs), is pleased to announce its partnership with Eureka Therapeutics, Inc., a clinical-stage biotechnology company dedicated to developing novel T‑cell therapies for both solid tumors and hematologic malignancies.
